Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)
Internal Hemorrhoids · HAE
De qué trata este estudio
El registro indica que este estudio recluta participantes. La disponibilidad puede variar por centro.
- Tipo de estudio
- De intervención
- Fase
- No aplica
- Rango de edad
- 18 años - 90 años
- Sexo admitido
- Todos los sexos
- Voluntarios sanos
- No aceptados
- Participantes
- 22 Estimado
Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.
Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.
Acerca de la investigación
Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve hemorrhoid related symptoms, especially bleeding. Initial reports of HAE have demonstrated that it both safe and effective. Following an initial clinic visit to determine trial candidacy, enrolled patients will be subsequently treated with HAE. Patients will be followed for a year with clinic follow-up visits at 1, 3, 6 and 12 months.
Leer la descripción completa
Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve hemorrhoid related symptoms, especially bleeding. Initial reports of HAE have demonstrated that it both safe and effective. However, the initial data is limited due to variations in embolization techniques, few studies with prospective long-term follow-up, and studies focusing on patients with only severe symptoms. Further research is needed to understand the specific long-term effectiveness of different embolization materials in a population that more accurately reflects the large number of patients with hemorrhoidal disease who would likely benefit from HAE. The proposed research project includes 22 patients with symptomatic internal hemorrhoids. Following an initial clinic visit to determine trial candidacy, enrolled patients will be subsequently treated with HAE. Patients will be followed for a year with clinic follow-up visits at 1, 3, 6 and 12 months.
¿Quién podría participar?
La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.
Inclusion Criteria:
- Age 18 to 90 years
- Ability to give written informed consent and to comply with the follow-up visits
- Symptomatic hemorrhoidal disease with French Bleeding Score (FBS) of at least four out of nine
- Refusal of or contraindication to surgery
- Refusal of or contraindication to other minimally invasive hemorrhoid treatments
- Grade I to III hemorrhoids
- Previous anoscopy or colonoscopy demonstrating internal hemorrhoids within 1 year
- Supply of the CCR from either the SRA or MRA on intra-procedural angiogram prior to embolization
Exclusion Criteria:
- Asymptomatic patients
- Patients who ever had previous colorectal surgery
- Grade IV hemorrhoids
- Colorectal disease other than hemorrhoids that could result in bleeding
- Anatomic findings on CTA that would preclude successful embolization
- Contraindication to iodinated contrast
- Inability to give written informed consent
- Active infection or malignancy
- Recent (within 12 months) or active cigarette use
- History of inflammatory bowel disease
- Uncorrectable bleeding diathesis
- Presence of portal hypertension or rectal varices seen on pre-procedure CTA or anoscopy/colonoscopy
- No SRA or MRA supply to the CCR seen intra-procedural angiogram
Tratamiento, grupos y participación
El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.
- Asignación
- No aplica
- Enmascaramiento
- Sin enmascaramiento
Hemorrhoidal artery embolization
Patients in this arm will undergo hemorrhoidal artery embolization (HAE) for treatment of symptomatic internal hemorrhoids
Procedure: Hemorrhoidal artery embolization
Hemorrhoidal artery embolization PROCEDURE
Hemorrhoidal artery embolization (HAE) involves the deliberate blockage of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve symptoms related to internal hemorrhoids, especially bleeding.
Qué evalúan los investigadores
Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.
Medidas principales
Proportion of patients with decrease in bleeding related symptoms of internal hemorrhoids as defined as a two-point decrease in French Bleeding Score
Plazo: From baseline to 12 months post procedure
No informado en este registro.
Medidas secundarias
Proportion of technically successful HAE procedures
Plazo: From baseline to 12 months post procedure
No informado en este registro.
Change in non-bleeding related symptoms of internal hemorrhoids as measured by the Hemorrhoid Disease Symptom Score (HDSS)
Plazo: From baseline to 12 months post procedure
The Hemorrhoidal Disease Symptom Score (HHDS) is a widely used questionnaire used by health professionals to evaluate the condition of patients with hemorrhoids. It can be self-administered and asks patients to rate the frequency and intensity of five primary symptoms: pain, itching, bleeding, soiling, and prolapse. Each symptom is rated on a scale of 0 to 4, with 0 indicating no symptoms and 4 indicating the most severe symptoms. The total HDSS score ranges from 0 to 20, with higher scores indicating more severe hemorrhoidal disease.
Change in non-bleeding related symptoms of internal hemorrhoids as measured by the Short Health Scale-Hemorrhoidal Disease (SHSHD)
Plazo: From baseline to 12 months post procedure
The Short Health Scale-Hemorrhoidal Disease questionnaire is a validated tool used to assess the impact of hemorrhoidal disease on a patient's health-related quality of life. It can be self-administered and measures four key dimensions: symptom load, functional status, disease-specific worries, and general well-being. Each symptom is rated on a scale of 1 to 7, with 1 indicating no symptoms and 7 indicating the most severe symptoms. The total SHSHD score ranges from 4 to 28, with higher scores indicating more severe hemorrhoidal disease.
Change in pain related to as measured by the Visual Analog Scale (VAS)
Plazo: From baseline to 12 months post procedure
The Visual Analog Scale (VAS) is a validated commonly used pain score. The VAS ranges from 0 to 10, with higher scores indicated higher pain levels.
Change in concomitant hemorrhoid medical therapy
Plazo: From baseline to 12 months post procedure
No informado en este registro.
Level of patient satisfaction after HAE as determined by patient satisfaction questionnaire
Plazo: From baseline to 12 months post procedure
Patient satisfaction will be determined by a patient satisfaction questionnaire with the following four options: very satisfied, satisfied, a little satisfied, and unsatisfied
Proportion of patients requiring subsequent non-surgical internal hemorrhoid procedures
Plazo: From baseline to 12 months post procedure
No informado en este registro.
Proportion of patients requiring surgical management of their internal hemorrhoids
Plazo: From baseline to 12 months post procedure
No informado en este registro.
Revisa las tablas completas y sus limitaciones en el registro oficial.
Abrir resultados oficiales ↗Centros de investigación (1)
El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.
1 centros
University of California, Los AngelesLos Angeles, California, United StatesReclutando
Equipo y fechas
- Patrocinador principal
- University of California, Los Angeles
- Inicio del estudio
- 5 ago 2025 Real
- Finalización primaria
- 30 sept 2028 Estimado
- Finalización del estudio
- 30 sept 2029 Estimado
- Primera publicación
- 18 sept 2025 Real
- Última actualización
- 10 nov 2026 Real
Contactos oficiales del estudio
Título oficial del estudio
Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)
Consulta a Wellness Clinical Research
Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.
Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.
Consultado: 12 nov 2026 · Última actualización del registro: 10 nov 2026
